Immune Checkpoint Dysregulation in Aneurysmal Subarachnoid Hemorrhage A Prospective Study of sCTLA-4 and sPD-L1 as Biomarkers of Symptomatic Vasospasm /
Aneurysmal subarachnoid hemorrhage (aSAH) is a severe stroke subtype often complicated by symptomatic cerebral vasospasm (sVP), contributing to delayed cerebral ischemia and poor outcomes. Immune dysregulation, particularly T-cell imbalances and pro-inflammatory cytokines, is implicated in vasospasm...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2025
|
| Sorozat: | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
26 No. 17 |
| Tárgyszavak: | |
| doi: | 10.3390/ijms26178228 |
| mtmt: | 36298925 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/38497 |
| LEADER | 02365nab a2200289 i 4500 | ||
|---|---|---|---|
| 001 | publ38497 | ||
| 005 | 20251211092801.0 | ||
| 008 | 251211s2025 hu o 000 eng d | ||
| 022 | |a 1661-6596 | ||
| 024 | 7 | |a 10.3390/ijms26178228 |2 doi | |
| 024 | 7 | |a 36298925 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Várnai Réka | |
| 245 | 1 | 0 | |a Immune Checkpoint Dysregulation in Aneurysmal Subarachnoid Hemorrhage |h [elektronikus dokumentum] : |b A Prospective Study of sCTLA-4 and sPD-L1 as Biomarkers of Symptomatic Vasospasm / |c Várnai Réka |
| 260 | |c 2025 | ||
| 300 | |a 15 | ||
| 490 | 0 | |a INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |v 26 No. 17 | |
| 520 | 3 | |a Aneurysmal subarachnoid hemorrhage (aSAH) is a severe stroke subtype often complicated by symptomatic cerebral vasospasm (sVP), contributing to delayed cerebral ischemia and poor outcomes. Immune dysregulation, particularly T-cell imbalances and pro-inflammatory cytokines, is implicated in vasospasm development. Soluble immune checkpoint proteins—CTLA-4 (sCTLA-4) and PD-L1 (sPD-L1)—regulate immune homeostasis and may serve as biomarkers or modulators of inflammation in aSAH. This prospective cohort study included 179 aSAH patients, divided into sVP+ (n = 48) and sVP− (n = 131), plus 50 healthy controls. Serum sCTLA-4 and sPD-L1 levels were measured on days 1, 5, and 9 post-ictus using Luminex xMAP. Associations with clinical outcomes were analyzed using non-parametric statistics and hierarchical clustering. Both sCTLA-4 and sPD-L1 were significantly elevated in sVP+ patients versus sVP− and controls, increasing over time. sCTLA-4 was significantly higher in sVP+ on days 5 (p = 0.001) and 9 (p < 0.001), and sPD-L1 on days 5 and 9 (both p < 0.001). Clustering revealed distinct expression patterns between sVP+ and sVP− groups. Elevated sCTLA-4 and sPD-L1 levels are associated with sVP after aSAH and may serve as biomarkers for early immune dysfunction, offering insights into potential therapeutic targets. | |
| 650 | 4 | |a Általános orvostudomány | |
| 700 | 0 | 1 | |a Szebeni Gábor |e aut |
| 700 | 0 | 1 | |a Gémes Nikolett |e aut |
| 700 | 0 | 1 | |a Schwarcz Attila |e aut |
| 700 | 0 | 1 | |a Molnár Tihamér |e aut |
| 700 | 0 | 1 | |a Oláh Csaba Zsolt |e aut |
| 700 | 0 | 1 | |a Csécsei Péter |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/38497/1/Varnai.pdf |z Dokumentum-elérés |